U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07477405) titled 'Drug-coatEd Balloon Multicentric Registry in Spain and PORTugal' on March 13.
Brief Summary: Drug-eluting stents (DES) have been the main treatment option for coronary angioplasty (PCI) for many years. The antiproliferative drug in DES has the effect of preventing in-stent restenosis, which is typically a consequence of intimal hyperplasia, a characteristic phenomenon of bare metal stents (BMS).
DES have shown to be safe and effective in many clinical and anatomical scenarios. There are, however, several caveats to DES, like restenosis, thrombosis, accelerated atherosclerosis, impossibility of surgical revascularization and disrup...